Abstract | BACKGROUND: METHODS: Six-month-old female SHR were randomly selected in six groups. Two control groups (SH(6), SH(12)) received vehicle. Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w. i.v.) twice in a 3-week interval. Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR. Animals were killed after 6 or 12 weeks, respectively. Haemodynamic measurements were performed on anaesthetized animals, blood and urine samples were taken for biochemical analysis and the left kidney was processed for morphological studies. RESULTS: CONCLUSION:
|
Authors | Nevena Mihailovic-Stanojevic, Djurdjica Jovovic, Zoran Miloradovic, Jelica Grujic-Milanovic, Mirjana Jerkic, Jasmina Markovic-Lipkovski |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
(Nephrol Dial Transplant)
Vol. 24
Issue 4
Pg. 1142-50
(Apr 2009)
ISSN: 1460-2385 [Electronic] England |
PMID | 18987260
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Antihypertensive Agents
- Antineoplastic Agents
- Doxorubicin
- Losartan
|
Topics |
- Angiotensin II Type 1 Receptor Blockers
(therapeutic use)
- Animals
- Antihypertensive Agents
(therapeutic use)
- Antineoplastic Agents
(adverse effects)
- Blood Pressure
(drug effects)
- Disease Models, Animal
- Disease Progression
- Doxorubicin
(adverse effects)
- Female
- Hemodynamics
- Kidney
(drug effects)
- Kidney Diseases
(chemically induced, drug therapy)
- Losartan
(therapeutic use)
- Rats
- Rats, Inbred SHR
|